| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71b3be70086419df7430dcf0abc1da93 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 |
| filingDate |
2002-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc0eef3de889ea581e501018a28e2a86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faf5e3426b5f62b0e63cf9581dd01130
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5223703438d01e0dd05b578af4c996a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00d82e4c7e4d8d2b5cb5f93ab0280102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4360a9d84957aee79b87c6fe21c0143 |
| publicationDate |
2003-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003124115-A1 |
| titleOfInvention |
Fusion protein having enhanced in vivo activity of erythropoietin |
| abstract |
The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016176940-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007129293-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014159813-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10428129-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008014193-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013362474-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7645733-B2 |
| priorityDate |
2001-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |